Xintian Pharma(SZ:002873)2025-05-12 09:46Group 1: Product Development - The company has two innovative drugs in development for cardiovascular diseases: XTBXH539 for acute ischemic stroke and XTHQT736 for chronic coronary syndrome, both showing clinical potential [2] - These candidates aim to provide neuroprotection and improve heart function, with a focus on reducing cardiac remodeling [2] Group 2: Automation and Smart Manufacturing - Since 2021, the company has integrated smart manufacturing into its operations, completing multiple automated production line upgrades [3] - A modern intelligent production capacity center has been established, enhancing supply chain efficiency and production quality [3] - The company plans to fully implement artificial intelligence in production by 2030, aligning with national smart manufacturing initiatives [3] Group 3: Investment and Financial Strategy - The company plans to invest CNY 250 million in building a pharmaceutical production line, primarily funded through self-owned capital and bank loans [4] - This investment is aimed at enhancing the company's competitive position and expanding its business scale, including contract manufacturing opportunities [4] - The company has terminated its share issuance for asset acquisition as of July 26, 2024, focusing on internal growth strategies [4]